NAT COMMUN:霍普金斯医学院研究人员发现卵巢癌早期诊断方式

2017-10-28 海北 MedSci原创

卵巢癌是妇科癌症死亡的主要原因,2 0年生存率低于30%,并且该情况在过去30年没有明显的改善。尽管研究人员做了大量的努力,但是各种筛查和治疗策略并没有导致整体生存率的提高。

卵巢癌是妇科癌症死亡的主要原因,2 0年生存率低于30%,并且该情况在过去30年没有明显的改善。尽管研究人员做了大量的努力,但是各种筛查和治疗策略并没有导致整体生存率的提高。改善卵巢癌诊断和治疗干预的主要挑战之一是我们对于该疾病的自然病史了解很少。已有的研究表明,输卵管癌可能是高级别浆液性卵巢癌(HGSOC)的前体,但是至今为止,这一假设的进化学证据是有限的。

来自霍普金斯大学医学院的研究人员在9名患者中使用全基因组测序,和激光捕获显微切割输卵管病变(p53特征,浆液性输卵管上皮内癌(STICs)和输卵管癌)),卵巢癌和转移瘤进行研究。

研究人员发现,卵巢癌中的大多数肿瘤特异性改变在STICs中也存在,包括影响TP53,BRCA1,BRCA2或PTEN的特征。进化学分析显示,p53特征和STICs是卵巢癌的前兆。研究人员还确定了STIC发展与卵巢癌发生之间存在7年的窗口,之后迅速转移。

因此,研究人员的结果帮助我们了解卵巢癌的病因,并有助于该疾病的预防,早期检测和治疗干预。


原始出处:

S. Intidhar Labidi-Galy et al. High grade serous ovarian carcinomas originate in the fallopian tubeNature Communications, 2017; 8 (1) DOI: 10.1038/s41467-017-00962-1


本文系梅斯医学(MedSci)原创编译整理,转载需授权! 


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1859786, encodeId=6a511859e86d0, content=<a href='/topic/show?id=f0a6342e2b0' target=_blank style='color:#2F92EE;'>#医学院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34272, encryptionId=f0a6342e2b0, topicName=医学院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Sep 30 19:18:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907517, encodeId=a113190e517a6, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Fri Feb 02 23:18:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087177, encodeId=c8ef208e177a0, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Feb 17 10:18:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882576, encodeId=df9518825e631, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Nov 19 06:18:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382674, encodeId=d93a13826e429, content=<a href='/topic/show?id=1f4e5946422' target=_blank style='color:#2F92EE;'>#早期诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59464, encryptionId=1f4e5946422, topicName=早期诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Oct 30 10:18:00 CST 2017, time=2017-10-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1859786, encodeId=6a511859e86d0, content=<a href='/topic/show?id=f0a6342e2b0' target=_blank style='color:#2F92EE;'>#医学院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34272, encryptionId=f0a6342e2b0, topicName=医学院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Sep 30 19:18:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907517, encodeId=a113190e517a6, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Fri Feb 02 23:18:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087177, encodeId=c8ef208e177a0, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Feb 17 10:18:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882576, encodeId=df9518825e631, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Nov 19 06:18:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382674, encodeId=d93a13826e429, content=<a href='/topic/show?id=1f4e5946422' target=_blank style='color:#2F92EE;'>#早期诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59464, encryptionId=1f4e5946422, topicName=早期诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Oct 30 10:18:00 CST 2017, time=2017-10-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1859786, encodeId=6a511859e86d0, content=<a href='/topic/show?id=f0a6342e2b0' target=_blank style='color:#2F92EE;'>#医学院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34272, encryptionId=f0a6342e2b0, topicName=医学院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Sep 30 19:18:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907517, encodeId=a113190e517a6, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Fri Feb 02 23:18:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087177, encodeId=c8ef208e177a0, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Feb 17 10:18:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882576, encodeId=df9518825e631, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Nov 19 06:18:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382674, encodeId=d93a13826e429, content=<a href='/topic/show?id=1f4e5946422' target=_blank style='color:#2F92EE;'>#早期诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59464, encryptionId=1f4e5946422, topicName=早期诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Oct 30 10:18:00 CST 2017, time=2017-10-30, status=1, ipAttribution=)]
    2018-02-17 liuli5079
  4. [GetPortalCommentsPageByObjectIdResponse(id=1859786, encodeId=6a511859e86d0, content=<a href='/topic/show?id=f0a6342e2b0' target=_blank style='color:#2F92EE;'>#医学院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34272, encryptionId=f0a6342e2b0, topicName=医学院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Sep 30 19:18:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907517, encodeId=a113190e517a6, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Fri Feb 02 23:18:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087177, encodeId=c8ef208e177a0, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Feb 17 10:18:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882576, encodeId=df9518825e631, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Nov 19 06:18:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382674, encodeId=d93a13826e429, content=<a href='/topic/show?id=1f4e5946422' target=_blank style='color:#2F92EE;'>#早期诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59464, encryptionId=1f4e5946422, topicName=早期诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Oct 30 10:18:00 CST 2017, time=2017-10-30, status=1, ipAttribution=)]
    2017-11-19 liye789132251
  5. [GetPortalCommentsPageByObjectIdResponse(id=1859786, encodeId=6a511859e86d0, content=<a href='/topic/show?id=f0a6342e2b0' target=_blank style='color:#2F92EE;'>#医学院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34272, encryptionId=f0a6342e2b0, topicName=医学院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Sep 30 19:18:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907517, encodeId=a113190e517a6, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Fri Feb 02 23:18:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087177, encodeId=c8ef208e177a0, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Feb 17 10:18:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882576, encodeId=df9518825e631, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Nov 19 06:18:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382674, encodeId=d93a13826e429, content=<a href='/topic/show?id=1f4e5946422' target=_blank style='color:#2F92EE;'>#早期诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59464, encryptionId=1f4e5946422, topicName=早期诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Oct 30 10:18:00 CST 2017, time=2017-10-30, status=1, ipAttribution=)]

相关资讯

[CSCO领袖三人行]如何解决卵巢癌早期筛查的难题?吴令英、Oliver Dorigo和饶建宇教授分享经验

2017年9月27日~30日,第20届全国临床肿瘤学大会暨2017年中国临床肿瘤学会(CSCO)年会于厦门召开。2017 CSCO分别开设了卵巢癌专场、宫颈癌和宫内膜癌专场。专家阵容强大,不仅有来自美国的杰出讲者,还集结了我国香港、台湾和大陆各省市的知名妇瘤专家,针对近年来领域内的热点、难点和争议性问题进行探讨。

Int J Cancer:偏头痛并不影响侵袭性卵巢癌的风险

偏头痛是一种常见的原发性头痛,它的主要患病人群为女性。最近的研究认为,偏头痛与激素有关的癌症相关;然而偏头痛和卵巢癌之间潜在的关联尚未研究。

肿瘤治疗电场为复发性卵巢癌患者带来新希望,无进展生存期延长两倍!

一项重磅2期临床试验致力于研究肿瘤治疗电场(下文简称为“TTFields”)在结合每周一次紫杉醇时对于复发性卵巢癌的疗效。美国癌症研究协会将亲自见证这一结果。

Radiology:附件囊肿需不需要随访?怀疑单纯附件囊肿中卵巢肿瘤的发病率

一般附件囊肿是指卵巢囊肿。卵巢囊肿是女性生殖器官的一种常见的良性肿瘤,中医称"石瘕"、"肠覃"。分粘液性囊腺瘤、浆液性囊腺瘤,良性畸胎瘤、纤维瘤、含睾丸母细胞瘤等类型,多有恶变的可能,常见于20-50岁妇女。本研究旨在评价偶然CT发现的单纯附件囊肿中恶性肿瘤的发病率,从而确定单纯良性表现的囊肿是否需要随访观察,并将结果发表在Radiology上。

J Ovarian Res:RHAMM的表达升高与卵巢癌进展相关

研究发现,透明质酸介导的运动受体(RHAMM)表达升高与多种癌症疾病的进展、侵袭性表型及预后不良相关,然而,RHAMM在卵巢癌(OC)中的作用目前尚未阐明。因此,本研究旨在评估RHAMM在上皮性OC中的作用。Western免疫印迹、免疫组织化学染色和酶联免疫吸附测定显示,尽管正常卵巢表皮上皮中RHAMM几乎没有表达,但是浆液性OC患者的临床组织切片、网膜转移、尿液以及细胞裂解物中的RHAMM的表达

NCCN临床实践指南:遗传家族高风险评估-乳腺癌和卵巢癌(2018.V1)

2017年10月,美国国家综合癌症网络(NCCN))发布了遗传/家族高风险评估-乳腺癌和卵巢癌指南2018年第1版。指南主要内容包括: 指南更新摘要 乳腺癌和/或宫颈癌的遗传学评估 BRCA相关性乳腺癌和/宫颈癌综合征 BRCA突变阳性的管理 李法美尼症候群的管理 Cowden综合征/错构瘤肿瘤综合症的管理 多基因检测